Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Neurourology and Urodynamics|August 28, 2019
The effects of microenergy acoustic pulses on animal model of obesity-associated stress urinary incontinence. Part 2: In situ activation of pelvic floor and urethral striated muscle progenitor cellsNing Kang, Dongyi Peng, Bohan Wang, et al.
BMC Cancer|April 10, 2023
Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarkerYumei Tang, Ye Lei, Peng Gao, et al.
The Lancet. Oncology|April 13, 2026
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trialAlicia K Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas, et al.
Journal for Immunotherapy of Cancer|May 10, 2022
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 studyYuan-Yuan Qu, Zhongquan Sun, Weiqing Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2021
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket StudyYuan-Yuan Qu, Hai-Liang Zhang, Hongqian Guo, et al.
BMC Medical Genomics|May 5, 2022
Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort studyYouyan Guan, Xiaobing Wang, Kaopeng Guan, et al.
Cancer Communications (London, England)|December 17, 2022
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitorsFei Liu, Zixian Wang, Xiaofan Li, et al.
Chronic Diseases and Translational Medicine|March 7, 2024
Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity resultsLinrui Gao, Ran Wei, Shirui Qin, et al.
ACS Nano|March 10, 2026
A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in Bladder CancerYunhao Gao, Feiya Yang, Lu Yin, et al.
Journal of Translational Medicine|March 15, 2023
Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancerSujun Han, Taoping Shi, Yuchen Liao, et al.
Pageof 16